Anumana wins FDA breakthrough status for AI algorithm to detect PH
Related Articles
New Ventures To Use AI To Target Heart Disease
Innovator News: Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from…{post_date: F d, Y}
Anumana Collaborates with Novartis Pharmaceuticals Corporation
AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…{post_date: F d, Y}
FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI
Pharma File: Anumana has announced the FDA had granted breakthrough Device Designation to its AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. Breakthrough Device Designations recognise novel innovations demonstrating potential…{post_date: F d, Y}
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions…{post_date: F d, Y}